Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.55 |
| ▸ | USP2 | O75604 | 13/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | RHOA | P61586 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095963 | 0.93 | LMNA (0.54) | CYP3A4USP2MAPK1TSHRRHOA | |
| SCHEMBL3091158 | 0.87 | ALDH1A1 (0.52) | CYP3A4USP2TSHRCYP1A2ALDH1A1 | |
| SCHEMBL3081032 | 0.85 | CYP3A4 (0.56) | CYP3A4USP2MAPK1TSHRCYP1A2 | |
| SCHEMBL3080049 | 0.85 | PROKR1 (0.53) | CYP3A4USP2TSHRCYP1A2ALDH1A1 | |
| SCHEMBL3085181 | 0.84 | ALDH1A1 (0.52) | CYP1A2ALDH1A1 | |
| SCHEMBL3096010 | 0.84 | ALDH1A1 (0.63) | CYP3A4USP2TSHRCYP1A2ALDH1A1 | |
| SCHEMBL3079273 | 0.83 | ALDH1A1 (0.51) | CYP3A4USP2TSHRCYP1A2ALDH1A1 | |
| SCHEMBL3086931 | 0.82 | ALDH1A1 (0.55) | CYP3A4USP2MAPK1TSHRCYP1A2 | |
| SCHEMBL3081026 | 0.82 | LMNA (0.53) | CYP3A4CYP1A2ALDH1A1GRIN2B | |
| SCHEMBL3075559 | 0.82 | ALDH1A1 (0.50) | CYP3A4USP2MAPK1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790898-B2 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2010-09-07 | — | — | US | claimed |
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-07-26 | — | — | US | claimed |
| US-7790898-B2 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | OPRK1, OPRD1, OPRL1 | CYP3A4 113/4885USP2 4164/4885MAPK1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.